我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

温阳解毒方联合肝动脉化疗栓塞术治疗中晚期肝癌患者的疗效评价(PDF)

《云南中医学院学报》[ISSN:1000-2723/CN:53-1048/R]

期数:
2017年06期
页码:
22-25
栏目:
临床研究
出版日期:
2018-03-19

文章信息/Info

Title:
Clinical Research of Wenyang Jiedu Formula with TACE in the Treatmentof Advanced Primary Hepatic Carcinoma
作者:
宋雅楠庄菊花张遂亮王国玉倪晶何赛飞夏伟△
上海中医药大学附属第七人民医院,上海 200137
Author(s):
SONG Yanan ZHANG Juhua ZHANG Suiliang WANG Guoyu NI Jing HE Saifei XIA Wei
The 7th People’s Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200137 China
关键词:
原发性肝癌 温阳解毒方 肝动脉化疗栓塞术 转移 中药
Keywords:
primary hepatic carcinoma Wenyang Jiedu formula transcatheter arterial chemoembolization metastasis traditional Chinese medicine
分类号:
R735.7
DOI:
10.19288/j.cnki.issn.1000-2723.2017.06.006
文献标识码:
A
摘要:
目的 观察温阳解毒方联合肝动脉化疗栓塞术(transcatheter arterial chemoembolization,TACE)治疗中晚期肝癌的临床疗效,探索中晚期肝癌的中西医结合治疗模式。方法 80例中晚期肝癌患者经TACE治疗后随机分为对照组和治疗组,对照组不服用任何药物,治疗组服用温阳解毒方,比较2组患者疗效、生存期、肝功能、甲胎蛋白、KPS评分、肿瘤复发和转移情况等差异。结果 治疗组和对照组患者肿瘤缓解率和稳定率比较,差异无统计学意义(P>0.05)。治疗组和对照组中位生存期分别为10个月和7个月;2组生存率比较,治疗组高于对照组,但差异无统计学意义(P>0.05)。治疗组肝功能指标显著优于对照组,甲胎蛋白显著低于对照组,KPS评分显著高于对照组,差异具有统计学意义(P<0.05)。治疗组术后3个月肝外转移灶低于对照组,差异具有统计学意义(P<0.05)。结论 温阳解毒方联合TACE能增强中晚期肝癌患者治疗效果,改善肝功能,尤其可减少肝癌术后转移,本研究为肝癌的中西医结合治疗提供借鉴。
Abstract:
Objective To observe the clinical effects of Wenyang Jiedu(WYJD) formula with TACE on advanced primary hepatic carcinoma(PHC), and explore the treatment model of integrated Chinese and Western medicines for advanced PHC. Methods 80 advanced PHC patients were randomly divided into control group and treatment group after TACE. The treatment group was treated with WYJD formula, while the control group with nothing. Clinical effects, survival time, liver function, APF, KPS scores, tumor recurrence and metastasis were detected. Results There were no significant differences in remission rate, stability rate and survival rate between treatment group and control group(P>0.05). The median survival time of treatment group and control group were 10 months and 7 months, respectively. Liver functions were improved, AFP value significantly decreased, KPS scores significantly increased, and metastasis was better in treatment group(P<0.05). Conclusion WYJD formula had a good effect on advanced PHC, especially on inhibiting liver metastasis. The study provided an experimental basis for integrated Chinese and Western medicines of PHC.

参考文献/References

[1] Narsinh KH,Duncan DP,Newton IG,et al. Liver-directed therapy for hepatocellular carcinoma[J]. Abdom Radiol(NY),2018,43(1):203-217
[2] Bai K,Cao Y,Huang C,et al. Association of histone methyltransferase G9a and overall survival after liver resection of patients with hepatocellular carcinoma with a median observation of 40 months[J]. Medicine,2016,95(2):e2493.
[3] Nishikawa H,Inuzuka T,Takeda H,et al. Comparison of percutaneous radiofrequency thermal ablation and surgical resection for small hepatocellular carcinoma[J]. BMC Gastroenterology,2011,11(1):143.
[4] 李猛. 健脾活血方联合TACE术对肝癌患者生活质量的影响[J]. 陕西中医,2011,32(7):854-856.
[5] Xie H,Yu H,Tian S,et al. What is the best combination treatment with transarterial chemoembolization of unresectable hepatocellular carcinoma? a systematic review and network meta-analysis[J]. Oncotarget. 2017,8(59):100508- 100523.
[6] 石芳毓,娄丽丽,谢吻,等. 中药注射剂联合肝动脉插管栓塞化疗术治疗肝癌的网状Meta分析[J]. 中国实验方剂学杂志,2016,22(10):180-187.
[7] 张百红,王湘辉,凌昌全. 中药治疗晚期肝癌的生存期分析[J]. 成都中医药大学学报,2009,32(3):13-16.
[8] 刘德明. 中晚期肝癌患者经中药联合介入治疗的多层螺旋CT影像及肝功能动态观察[J]. 临床医学研究与实践,2017,2(21):98-99.
[9] 李照,朱继业. 《原发性肝癌诊疗规范(2017年版)》解读[J]. 临床肝胆病杂志,2017,33(9):1655-1657.
[10] Sorski L,Melamed R,Matzner P,et al. Reducing liver metastases of colon cancer in the context of extensive and minor surgeries through β-adrenoceptors blockade and COX2 inhibition[J]. Brain Behav Immun,2016,19(58):91-98.
[11] Kudo M,Ueshima K,Kubo S,et al. Response evaluation criteriain cancer of the liver(RECICL)(2015 revised version)[J]. Hepatol Res,2016,46(1):3-9.
[12] 许军,施长杲,秦汉林,等. 益气养阴解毒方对晚期肝癌介入治疗减毒增效作用的临床研究[J]. 安徽医药,2017,21(3):541-545.
[13] 刘海荣,黄国红. 介入热化疗栓塞术对中晚期肝癌的治疗效果观察[J]. 实用中西医结合临床,2015,15(12):57-58.
[14] 曹继刚,邱幸凡,陈月雀,等. 原发性肝癌的基本病机及治则探讨[J]. 中医药学报,2008,36(4):28-29.
[15] 庄陈英,邵铭. 邵铭治疗原发性肝癌经验[J]. 四川中医,2011,29(10):15-16.
[16] Yang K,Zhang XM,Yang L,et al. Advanced imaging techniques in the therapeutic response of transarterial chemoembolization for hepatocellular carcinoma[J]. World J Gastroenterol,2016,22(20):4835-4847.
[17] Lee JW,Oh JK,Chung YA,et al. Prognostic significance of 18F-FDG uptake in hepatocellular carcinoma treated with transarterial chemoembolization or concurrent chemoradiotherapy:a multicenter retrospective cohort study[J]. J Nucl Med,2016,57(4):509-516.
[18] 贺天临,马璐璐,谢国群,等. 清热解毒方配合TACE治疗中晚期肝癌的临床疗效观察[J]. 上海中医药杂志,2016,19(5):31-34.
[19] 李玉龙,孙保国,项婷,等. 健脾解毒方延长脾虚肝癌大鼠带瘤生存与MHCⅠ/MHCⅡ的关系[J]. 中药材,2014,37(3):454-460.
[20] 李菁,许利纯. 疏肝健脾解毒方联合肝动脉化疗栓塞术治疗原发性肝癌的临床研究[J]. 中国急救医学,2016,36(12S):113-114.

备注/Memo

备注/Memo:
* 基金项目: 国家自然科学基金(81703791);上海市浦东新区卫生系统重点学科群建设项目(PWZxq2014-12)
收稿日期: 2017 - 12- 10
作者简介: 宋雅楠(1989-),女,山西太原人,博士,助理研究员,研究方向:中药药理。
△通信作者: 夏伟,E-mail:awingxia@163.com
更新日期/Last Update: 2017-12-20